formulary
An approved list of drugs that a payer covers, often favoring cheaper generics, used as leverage to negotiate prices.
As defined in Marcia Angell on Big Pharma
Where it comes up · 4
- Robin Feldman on Drugs, Money, and Secret Handshakes4 claims
- Marcia Angell on Big Pharma3 claims
- Richard Epstein on Property Rights and Drug Patents 2/19/20072 claims
- Mark Cuban2 claims
Most important claims · 10 of 11Search all claims for “formulary” →
- The big three PBMs (CVS Caremark, Express Scripts, Optum Rx) put profits over everything by exploiting an opaque industry: contracts forbid disclosure, so they can tell different client companies different 'great prices' while neither knows the true cost or markup, and they even underpay contracted rebates because there's no way for clients to verify.Mark Cuban
- PBMs keep high-cost drugs on formulary and exclude cheaper biosimilars because they earn rebates on the expensive drug but not the cheaper alternative — for example Humira at $8,000/month pre-rebate (3-6k after rebate) versus the biosimilar Yusimry at $594, which the big three PBMs won't allow because there's no rebate, so they make more money keeping patients on the costly drug.Mark Cuban
- The formulary—a health plan's tiered list (often 5, sometimes 7 tiers) determining whether and at what level a drug is reimbursed—has become a tool by which PBMs and drug companies steer patients toward more expensive drugs, because a high-volume drug company can offer better rebate deals in exchange for excluding or disadvantaging rival drugs on the menu.Robin Feldman on Drugs, Money, and Secret Handshakes
- The rebate system, though complex, functions simply: drug companies share their monopoly rents by paying PBMs, hospitals, and doctors along the supply chain to ensure cheaper drugs are left out of formularies, all wrapped in secret deals that government and health-plan auditors cannot see.Robin Feldman on Drugs, Money, and Secret Handshakes
- All top-selling insulin drugs have extended their protection by at least 20 years, each piling on dozens of protections (one with 55), and these provide the volume positions that set up PBM deals so cheaper generic insulin—even from nonprofits—cannot get into health plan coverage and therefore cannot reach patients, despite insulin being a long-discovered 'magic bullet.'Robin Feldman on Drugs, Money, and Secret Handshakes
- Because prescription drug distribution flows overwhelmingly through health plans, a product not on the formulary won't get filled or substituted at the pharmacy and cannot enter the system, and a cheap-generic maker cannot afford the mass television advertising a brand company uses to reach patients—so getting off the formulary is not a workaround for reaching patients.Robin Feldman on Drugs, Money, and Secret Handshakes
- Government Medicaid purchasing and HMO formularies with bulk purchasing can lower prices by guaranteeing volume, and HMOs play rival drugs in a class against each other, which creates price variation where no two people pay the same price.Richard Epstein on Property Rights and Drug Patents 2/19/2007
- A major part of the problem beyond drug-company profit motive is that Americans pay for most medical care with other people's dollars, which removes the price discipline that would lead patients to choose cheap equivalent drugs and allows doctors who receive industry gifts to prescribe expensive new drugs.Marcia Angell on Big Pharma
- The Veterans Administration obtains probably the lowest drug prices in the country because it can threaten to switch to generics, while Medicare by law must pay whatever the drug companies charge, demonstrating how negotiating leverage drives prices.Marcia Angell on Big Pharma
- The Affordable Care Act secured pharmaceutical industry support by preserving the Medicare Prescription Drug Benefit's prohibition on the government bargaining for drug prices and by keeping drug importation from Canada and Europe illegal, both provisions Obama had campaigned against and then abandoned.Marcia Angell on Big Pharma